Stay updated on Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe study record was updated on November 16, 2026, and the University of Chicago Medical Center location in Chicago changed its status to “Not yet recruiting.” The contact phone number was reformatted without changing its digits.SummaryDifference0.5%

- Check11 days agoChange DetectedThe clinical trial record for the ovarian cancer immunotherapy study is now displayed instead of an error page, with details about participation criteria, interventions, locations, and study outcomes.SummaryDifference66%

- Check19 days agoChange DetectedThe site footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH-wide banner about the transition from “Artificial Intelligence” to “Super Intelligence” appeared, and the site revision label changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe site revision in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now renders a 403 Forbidden error instead of the study details, effectively blocking access to the IPROC record. The visible content shows a standard 403 layout and message.SummaryDifference20%

Stay in the know with updates to Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.